# Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

> **NCT02489448** · PHASE1,PHASE2 · COMPLETED · sponsor: **Yale University** · enrollment: 68 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** MEDI4736

## Key facts

- **NCT ID:** NCT02489448
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2021-06-15
- **Final completion:** 2021-08-02
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2022-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02489448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02489448, "Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02489448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*